Oncology/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis AstraZeneca looks to CRISPR to boost success rates George Underwood AstraZeneca, cancer, Cancer Research UK, CRIPR 0 Comment Between 2005 and 2010 AstraZeneca‘s success rates for taking drugs from candidate nomination to phase III completion were at 4%, below Share X AstraZeneca looks to CRISPR to boost success rates https://pharmaphorum.com/views-and-analysis/astrazeneca-crispr-boost-success-rates/
